Severe refractory asthma: current treatment options and ongoing research

Francesco Menzella MD, Francesca Bertolini MSc, PhD, Mirella Biava MSc, Carla Galeone MSc, Chiara Scelfo MD, Marco Caminati MD

Article Type

Review

Published

In this review, the different biological options available for the treatment of severe refractory asthma, their mechanism of action, and the overlapping aspects of their usage in clinical practice are discussed.

Read more

Impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis: an observational study from five Central and Eastern European countries

Daniela Opris-Belinski MD, PhD, Shandor F Erdes MD, PhD, Simeon Grazio MD, PhD, Ladislav Šenolt MD, PhD, Maja Hojnik MD, PhD, Orsolya Nagy MD, PhD, Diana Marina BSc, Sándor Szántó MD, PhD, DSc

Article Type

Original Research

Published

This study assessed the impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis in five Central and Eastern Europe countries.

Read more

Eosinophilic fasciitis: a case series with an emphasis on therapy and induction of remission

Rechelle Tull MD, William D Hoover III MD, Jacqueline F De Luca MD, William W Huang MD, MPH, Joseph L Jorizzo MD

Article Type

Original Research

Published

Eosinophilic fasciitis is an uncommon connective tissue disorder. Systemic corticosteroids can induce remission of disease; however, there is no universally accepted treatment ladder for eosinophilic fasciitis. This case series evaluates treatment efficacy in patients with eosinophilic fasciitis.

Read more

The biosimilars journey: current status and ongoing challenges

Igor Age Kos MD, Valderílio Feijó Azevedo MD, PhD, Daniel Egg Neto, Sérgio Cândido Kowalski MD, PhD

Article Type

Review

Published

Biosimilar products are already approved and marketed in several countries. This review focuses on remaining challenges regarding biosimilars, such as the lack of regulatory harmony, especially concerning naming, the marketed intended copies, the interchangeability, and the biosimilars in orphan diseases.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.